Cristina Saura, Principal Investigator of VHIO´s Breast Cancer & Melanoma Group, talks to JNCCN 360 – the recently launched interactive resource powered by the Journal of the National Comprehensive Cancer Network, about the LORELEI study findings on neoadjuvant letrozole plus taselisib vs letrozole plus placebo in postmenopausal patients with ER+/HER2– early breast cancer, as recently presented during a Proffered Paper Session at the 2017 ESMO Congress, 08 – 12 September, Madrid, Spain.
Carried out in collaboration with academic partners the Breast International Group (BIG), SOLTI Breast Cancer Research Group, and the Austrian Breast & Colorectal Cancer Study Group (ABCSG), and conducted in 85 sites across the world, this phase II study assessed the efficacy of adding taselisib to letrozole before surgery for the treatment of patients with operable early estrogen receptor positive and HER2-negative breast cancer.
She also discusses the pathways and intended action of targeting PI3K, and how these findings led to the development of an international, multicenter phase III trial in the metastatic setting – SANDPIPER.
To access the video click here.
